Biocon reported a strong turnaround in Q2FY26 with a net profit of Rs 84.5 crore against a loss of Rs 16 crore last year, driven by 21% YoY revenue growth to Rs 4,389 crore. Biosimilars led with 61% of revenue. The company also repaid key debts, aiming to boost margins and cut interest costs by FY27.